Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-38 is an inhibitor targeting the SARS-CoV-2 virus, demonstrating significant potential in antiviral research. This compound exhibits favorable oral bioavailability in murine models, achieving a bioavailability rate of 39.75%. It is relevant for studies focused on the development of therapeutics aimed at combating COVID-19 and related viral infections. -
SARS-CoV nsp14 Inhibitor
SARS-CoV-IN-4 is a potent inhibitor of the SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM. This compound offers specificity in targeting the N7-methyltransferase activity, making it a valuable tool for studying viral RNA modification processes. SARS-CoV-IN-4 is relevant for research applications related to antiviral drug discovery and the mechanistic understanding of SARS-CoV replication and pathogenesis. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-44 is a potent inhibitor targeting SARS-CoV-2, effectively blocking viral replication with an EC50 of 0.6 μM. The compound demonstrates minimal cytotoxicity in Calu-3 cells, making it suitable for antiviral research. Its profile supports investigations into therapeutic strategies against SARS-CoV-2 infection. -
SARS-CoV-2 Inhibitor
Crepidiaside B is a natural compound derived from Cichorium intybus that functions as an inhibitor of the SARS-CoV-2 spike glycoprotein. This compound exhibits antiviral activity and is utilized in research studies focused on coronavirus disease 2019 (COVID-19) and the mechanisms of viral entry into host cells. Its potential therapeutic implications make it a valuable tool in the ongoing efforts to combat SARS-CoV-2. -
SARS-CoV-2 Inhibitor
CMX990 is an inhibitor of the SARS-CoV-2 3CL protease, demonstrating potent antiviral activity with EC90 values of 9.6 nM in human bronchial epithelial cells and 101 nM in HeLa-ACE2 cells. This reagent exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties, making it suitable for research in virology and drug development targeting coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-12 is an inhibitor of the SARS-CoV-2 main protease (Mpro), a critical enzyme in the viral life cycle. This compound demonstrates potent antiviral activity, making it a valuable tool for studying viral replication mechanisms and developing therapeutic strategies against COVID-19. Its specificity for Mpro allows for focused research on the inhibition of SARS-CoV-2 and the evaluation of potential antiviral agents. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-20 is a targeted inhibitor of SARS-CoV-2 with an effective concentration (EC50) of 6.5 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for research applications focused on infectious diseases, particularly COVID-19. Its inhibitory properties enable studies on viral replication and therapeutic interventions. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2-IN-12 is a potent inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), demonstrating a Ki value of 32.1 pM. This compound effectively prevents viral replication, making it a valuable tool for research applications focused on COVID-19. Its high potency and specificity aid in investigations aimed at understanding and developing therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 Mpro-IN-9 is a nonpeptidic, noncovalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2, exhibiting an IC50 of 0.085 μM. This compound demonstrates effective inhibition of viral replication in SARS-CoV-2-infected Vero E6 cells, with an EC50 of 1.10 μM, while showing low cytotoxicity (CC50 > 50 μM). SARS-CoV-2 Mpro-IN-9 is significant for research applications focused on antiviral strategies against COVID-19 and the development of therapeutic agents. -
SARS-CoV-2 Mpro nhibitor
Artecanin is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), targeting key amino acid residues His41 and Cys145 within the enzyme's active site. By forming a stable complex with Mpro, Artecanin effectively disrupts the cleavage and maturation of viral precursor proteins, thereby inhibiting viral replication and invasion. This compound is relevant for research focused on COVID-19 and the development of antiviral strategies. -
SARS-CoV-2 NSP14 MTase Inhibitor
NSC111552 is a selective inhibitor of the SARS-CoV-2 NSP14 methyltransferase (MTase), demonstrating significant potency. It effectively disrupts FL-NAH binding to the NSP14 MTase with an IC50 value of 5.1 μM. This compound is valuable for research into SARS-CoV-2 replication processes and the development of antiviral therapies targeting the viral MTase activity. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-32 is a highly potent inhibitor of the SARS-CoV-2 3CLpro enzyme, characterized by an IC50 value of 0.109 μM. In addition to its inhibitory effects on SARS-CoV-2, this compound demonstrates antiviral activity against the coronavirus HCoV-OC43, with an EC50 of 1.99 μM. It is a valuable tool for researchers studying viral replication and therapeutic strategies against coronavirus infections. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-84 is a selective inhibitor of the SARS-CoV-2 3CL protease (3CL Pro), with an IC50 value of 369.5 nM. This compound demonstrates potent antiviral activity against SARS-CoV-2 and is valuable for research applications focused on developing therapeutic strategies for COVID-19. Its mechanism of action provides insights into viral replication processes, making it an essential tool for virology studies and drug discovery efforts targeting SARS-CoV-2. -
SARS-CoV-2 Mpro Inhibitor
M56-S2 iodide is a selective inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 value of 4.0 μM. This compound demonstrates favorable oral bioavailability and exhibits low toxicity based on ADMET predictions, indicating its potential as a therapeutic agent. M56-S2 iodide serves as a valuable tool in antiviral research, particularly in the study of SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
ZINC61142882 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase, exhibiting an IC50 value of 6 μM. This compound demonstrates antiviral activity by disrupting viral RNA cap methylation, which is essential for RNA stability and immune evasion. It is suitable for research focused on COVID-19 therapeutic development and the exploration of viral RNA modifications. -
SARS-CoV-2 Inhibitor
TO-195 hydrochloride is a protease inhibitor that specifically targets severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It exhibits antiviral activity and shows potential as a therapeutic agent for the study of coronavirus disease 2019 (COVID-19). This compound is valuable for researchers investigating SARS-CoV-2 protease mechanisms and developing novel antiviral strategies. -
SARS-CoV-2 Inhibitor
Antiviral agent 25 is a novel non-peptide analog that functions as a covalent inhibitor of SARS-CoV-2 3CLpro and PLpro. It demonstrates potent inhibitory activity against these proteases, with IC50 values of 0.118 µM and 0.448 µM, respectively. Additionally, antiviral agent 25 exhibits effective antiviral activity against SARS-CoV-2, showing an EC50 value of 7.249 µM. This compound is valuable for research on viral replication and inhibition in SARS-CoV-2 studies. -
SARS-CoV Inhibitor
XR8-69 is a potent inhibitor of the SARS-CoV-2 main protease (PLpro), demonstrating low micromolar antiviral activity in infected human cells. This compound is valuable for research focused on antiviral strategies against SARS-CoV-2, offering insights into the inhibition of viral replication and potential therapeutic avenues in COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-40 is a potent inhibitor of the SARS-CoV-2 virus, specifically targeting BA.1 and BA.5 variants. This compound demonstrates biological activity through its ability to inhibit viral infection in Calu3 lung cells, achieving IC50 values of 100 nM and 160 nM for the respective variants. SARS-CoV-2-IN-40 serves as a valuable tool for research focused on understanding and combating SARS-CoV-2 infections. -
SARS-Cov-2-Mpro inhibitor
GRL-190-21 is a potent inhibitor of SARS-CoV-2 main protease (Mpro), exhibiting a dissociation constant (Ki) of 0.04 nM. This compound demonstrates significant antiviral activity, with an effective concentration (EC50) of 0.26 μM in Vero E6 cells. GRL-190-21 effectively reduces the infectivity, replication, and cytopathic effects of SARS-CoV-2, while maintaining a favorable safety profile with minimal toxicity. This compound is valuable for research focused on antiviral drug development and elucidating coronavirus pathogenesis. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-45 is a potent inhibitor of the main protease (Mpro) of SARS-CoV-2, with IC50 values of 0.12 μM for HCoV-OC43 Mpro and 0.16 μM specifically for SARS-CoV-2 Mpro. This compound demonstrates effective antiviral activity, making it valuable for research into therapeutic strategies against COVID-19 and related coronaviruses. Its oral bioavailability further enhances its potential applications in drug development and infectious disease studies. -
SARS-CoV-2 3CLpro Inhibitor
Hydroxyethylamine is a selective inhibitor of the SARS-CoV-2 3CLpro enzyme, exhibiting an IC50 of approximately 10 μM in viral spread assays. This compound demonstrates potent antiviral activity, making it a valuable tool for research targeting SARS-CoV-2 replication and infection mechanisms. Its application is critical in the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 PLpro Inhibitor
SIMR3030 is a highly effective inhibitor of the SARS-CoV-2 PLpro enzyme, exhibiting an IC50 value of 0.0399 µg/mL. This compound demonstrates significant antiviral activity, reducing the expression levels of SARS-CoV spike, ORF1b, IFN-α, and IL-6 mRNA. Additionally, SIMR3030 has shown a favorable safety profile in murine models, making it a valuable reagent for research into COVID-19 therapeutics and fundamental coronavirus biology. -
SARS-CoV-2 3CLpro Inhibitor
D1N8 is an effective inhibitor of the SARS-CoV-2 3CLpro enzyme, demonstrating an IC50 value of 0.44 μM with a favorable CC50 greater than 20 μM. This compound is valuable for research focused on developing anti-SARS-CoV-2 agents aimed at inhibiting 3CLpro activity, contributing to the understanding of viral replication and potential therapeutic interventions. -
SARS-CoV-2 Exonuclease Inhibitor
Dexamethasone metasulfobenzoate sodium is an inhibitor of the SARS-CoV-2 exonuclease (ExoN), targeting the catalytic site to impede viral replication. This compound is valuable for research focused on SARS-CoV-2 mechanisms and can aid in the development of therapeutic strategies against COVID-19. Its specific interaction with ExoN may provide insights into viral RNA processing and fidelity. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-9 is a potent inhibitor targeting the main protease of SARS-CoV-2 by binding to subsites S1 and S2. This compound demonstrates significant antiviral activity, making it a valuable tool for research in understanding and developing treatments against COVID-19. Its application extends to studies focused on inhibiting viral replication and investigating the molecular mechanisms underpinning SARS-CoV-2 pathogenesis. -
SARS-CoV-2 Replication Inhibitor
Aranotin is a potent inhibitor of SARS-CoV-2 replication, targeting the Nsp15 viral protein. This compound demonstrates strong binding affinity, making it a promising candidate for inhibiting viral replication. Aranotin is suitable for research applications focused on understanding and combating COVID-19. -
SARS-CoV-2 NSP13 Helicase Inhibitor
FWM-3 is a potent inhibitor of the SARS-CoV-2 NSP13 helicase, a critical enzyme involved in viral replication. This compound exhibits strong antiviral activity, making it a valuable tool for research focused on the mechanisms of SARS-CoV-2. Its application is particularly relevant in studies aimed at developing therapeutic strategies against COVID-19 by targeting viral helicase functions. -
SARS-CoV-2 Mpro PROTAC Degrader
PROTAC SARS-CoV-2 Mpro degrader-2 is a highly effective PROTAC degrader targeting the main protease (Mpro) of SARS-CoV-2. This compound exhibits significant antiviral activity against various coronaviruses, including EC50 values of 10.8 μM for SARS-CoV-2, 1.6 μM for HCoV-OC43, and 6.5 μM for HCoV-229E. In Calu-3 cells, it demonstrates potent efficacy with an EC50 of 0.89 μM, making it a valuable tool for research focused on coronavirus biology and potential therapeutic interventions. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-7 is a reversible covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 1.4 µM. This compound plays a critical role in viral replication by inhibiting the protease activity, making it a valuable tool for research into antiviral strategies against COVID-19. Its application is particularly relevant in the study of SARS-CoV-2 protease mechanisms and the development of potential therapeutic agents. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-62 is a potent inhibitor of SARS-CoV-2 replication, demonstrating low cytotoxicity in cell culture models. This compound effectively inhibits viral replication in Vero E6 and Calu-3 cells, with EC50 values of 2.97 μM and 3.82 μM, respectively. It serves as a valuable tool in research aimed at understanding and combating SARS-CoV-2 infections. -
SARS-CoV-2 Inhibitor
F8-S43-S3 is a potent inhibitor of the SARS-CoV-2 main protease, demonstrating an IC50 of 9.69 μM. This compound is valuable for research applications aimed at understanding viral replication mechanisms and developing therapeutic strategies against COVID-19. Its selectivity and effectiveness make it a critical tool in the study of SARS-CoV-2's biology and in the search for antiviral agents. -
SARS-CoV-2 Nsp13 Inhibitor
MWAC-3429 is a potent inhibitor of the SARS-CoV-2 Nsp13 helicase, demonstrating robust antiviral activity against both SARS-CoV-2 and SARS-CoV-1. With EC50 values of 5.39 μM (nLuc assay) and 17.00 μM (CPE assay), MWAC-3429 exhibits low cytotoxicity in A549-hACE2 cells, with a CC50 greater than 50 μM. This compound is valuable for research into SARS-CoV infections and the mechanistic understanding of viral helicase inhibition. -
SARS-CoV Inhibitor
MI-30 is a potent inhibitor of the SARS-CoV-2 3CLpro with an IC50 of 17.2 nM, demonstrating significant efficacy in reducing viral load and lung lesions in mouse models of SARS-CoV-2 infection. This compound serves as a valuable tool in the study of coronavirus infections, facilitating research aimed at understanding viral mechanisms and the development of therapeutic strategies. -
SARS-CoV-2 Main Protease Inhibitor
SARS-CoV-2-IN-21 is a potent inhibitor of the SARS-CoV-2 main protease, exhibiting an IC50 of 5.3 μM. This compound, a penicillin sulfone benzyl C6 derivative, is instrumental in studying viral replication and pathogenesis. Its inhibitory action makes it a valuable tool for COVID-19 research and drug development. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-6 is a selective, covalent, irreversible inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 0.18 μM. This compound specifically targets Mpro without inhibiting key human cathepsins B, F, K, and L, or caspase 3. SARS-CoV-2 Mpro-IN-6 is suitable for research applications focused on understanding COVID-19 pathogenesis and developing therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 main protease Inhibitor
VPC285785 is a potent inhibitor of the SARS-CoV-2 main protease, exhibiting an IC50 of 0.8 μM and a Kd of 2.7 μM. This compound effectively disrupts the processing of viral polyprotein precursors, which is crucial for viral replication. In studies with MHV-infected mice, VPC285785 significantly lowered viral loads in the liver, brain, and spleen. This reagent is valuable for research focused on coronavirus infections and therapeutic development. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-18 is a potent inhibitor of the SARS-CoV-2 3C-like protease, exhibiting an IC50 of 45 nM. This compound plays a crucial role in viral replication by interrupting the cleavage of polyproteins necessary for SARS-CoV-2 maturation. It is primarily utilized in research aimed at developing antiviral strategies against COVID-19 and understanding the mechanisms of viral protease function. -
SARS-CoV-2 nsp13 Inhibitor
SARS-CoV-2 nsp13-IN-5 is a selective inhibitor of the SARS-CoV-2 non-structural protein 13 (nsp13), demonstrating IC50 values of 50 μM for ssDNA-ATPase and 55 μM for ssDNA+ ATPase activities. This compound plays a critical role in antiviral research targeting the replication machinery of SARS-CoV-2. SARS-CoV-2 nsp13-IN-5 is valuable for studies aimed at developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-63 is a potent inhibitor of SARS-CoV-2 replication, demonstrating low cytotoxicity. It effectively inhibits viral replication in Vero E6 and Calu-3 cells, with EC50 values of 1.99 μM and 1.92 μM, respectively. This compound is ideal for research applications focused on antiviral drug development and understanding SARS-CoV-2 pathogenesis. -
SARS-CoV 3CLpro Inhibitor
JZD-07 is a potent inhibitor of the SARS-CoV-2 main protease (3CLpro), a critical enzyme for viral replication. This compound effectively disrupts the viral life cycle, making it a valuable tool for studying SARS-CoV-2 infection and developing antiviral therapies. Its application in research can provide insights into the mechanisms of viral pathogenesis and the efficacy of potential inhibitors. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-97 is a specific inhibitor targeting the SARS-CoV-2 Nsp15 endoribonuclease, demonstrating an IC50 of 53.5 μM. This compound shows low cytotoxicity in A549-AT cells, with an IC50 of 134 μM, making it a valuable tool for studying SARS-CoV-2 biology and antiviral strategies. Its selective inhibition could aid in the development of therapeutic approaches against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-51 is an effective inhibitor targeting the fusion mechanism of the SARS-CoV-2 virus, particularly against the Omicron variant. This compound exhibits potent antiviral activity, inhibiting viral entry with EC50 values ranging from 0.82 to 5.45 μM. By directly interacting with the spike protein in its prefusion conformation, SARS-CoV-2-IN-51 serves as a valuable tool for research applications focused on COVID-19 therapeutic development and understanding viral entry mechanisms. -
SARS-CoV-2 NPro Inhibitor
SARS-CoV-2-IN-16 is a potent inhibitor of the SARS-CoV-2 nucleocapsid protein (NPro), demonstrating significant antiviral activity with an EC50 of 3.69 μM. This compound binds to NPro with a low KD value of 7.82 μM, indicating its efficacy as a high-affinity ligand. SARS-CoV-2-IN-16 is suitable for research applications focused on viral infection mechanisms and the development of therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 3CLpro-IN-14 is an orally active inhibitor of the SARS-CoV-2 3CL protease (3CLpro), a crucial target for antiviral therapy. This compound exhibits robust anti-SARS-CoV-2 activity with an EC50 value of 0.18 μM while displaying low cytotoxicity with a CC50 greater than 50 μM in Vero E6 cells. It is applicable in the research of COVID-19 therapies, particularly for understanding viral replication mechanisms and testing potential antiviral compounds. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-19 is a potent inhibitor of SARS-CoV-2, specifically targeting the viral helicase nsp13 with an EC50 of 8.8 μM. This compound demonstrates strong anti-SARS-CoV-2 activity, making it a valuable tool for studying COVID-19 and other human coronavirus outbreaks. Its mechanism suggests applications in infectious disease research, particularly in the development of antiviral therapeutics. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-99 is a potent inhibitor of the SARS-CoV-2 main protease, an essential enzyme for viral replication. This compound demonstrates significant antiviral activity, making it a valuable tool for research in the field of COVID-19 therapeutics. SARS-CoV-2-IN-99 can aid in studies aimed at developing effective antiviral strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
N-0920 is a highly potent TMPRSS2 inhibitor, exhibiting an IC50 of 0.35 nM. This compound effectively inhibits the entry of SARS-CoV-2 variants EG.5.1 and JN.1 in Calu-3 cells, demonstrating remarkable picomolar EC50 values of 300 pM and 90 pM, respectively. N-0920 is an essential tool for research into viral entry mechanisms and therapeutic strategies against SARS-CoV-2. -
SARS-CoV Inhibitor
PLpro-IN-7 is a potent inhibitor of the papain-like protease (PLpro) of SARS-CoV, demonstrating an IC50 of 3 nM. This compound exhibits significant antiviral activity, making it a valuable tool in the study of SARS-CoV replication and pathogenesis. PLpro-IN-7 is essential for research focusing on the development of therapeutics targeting coronavirus infections. -
SARS-CoV-2 Inhibitor
3-Deazaguanosine is an antiviral compound targeting SARS-CoV-2, exhibiting a potent inhibitory effect with an EC50 value of 1.14 μM and a high CC50 exceeding 200 μM in Vero E6 cells. This reagent demonstrates significant potential in mitigating the severity of COVID-19 pneumonia, making it a valuable tool for research in viral pathogenesis and therapeutic development against coronavirus infections.
